Pregled bibliografske jedinice broj: 1246055
Empirical second-line treatments in Europe: results from the European registry on H. pylori management (HP-EUREG)
Empirical second-line treatments in Europe: results from the European registry on H. pylori management (HP-EUREG) // 34th International Workshop on Helicobacter & Microbiota in Inflammation & Cancer
online, 2021. str. 27-29 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 1246055 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Empirical second-line treatments in Europe:
results from the European registry on H. pylori
management (HP-EUREG)
Autori
O. P. Nyssen , Á. Pérez-Aísa , D. Vaira , G. Fiorini , L. Rodrigo , A. Keco-Huerga , M. Castro- Fernández , J. Kupčinskas , L. Jonaitis , B. Tepes , L. Vologzhanina , M. Caldas , S. Martinez- Dominguez , E. Alfaro , A. Lucendo, L. Bujanda, T. Di Maira, J. Barrio, J. M. Huguet, J. Perez Lasala, D. Bordin, M. Leja, A. Gasbarrini, S. Georgopoulos, F. Lerang, P. Phull, T. Rokkas, O. Shvets, Y. Niv, D. Lamarque, F. Heluwaert, Ante Tonkić, M. Venerito, I. Simsek, V. Milivojevic, G. M Buzas, V. Lamy, W. Marlicz, L. Boyanova, P. Bytzer, L. Capelle, L. Kunovský, A. Goldis, C. Beglinger, M. Espada , I. Puig, F. Mégraud, C. O’Morain, J. P. Gisbert
Kolaboracija
Hp-EuReg Investigators
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
34th International Workshop on Helicobacter & Microbiota in Inflammation & Cancer
/ - , 2021, 27-29
Skup
International Workshop on Helicobacter and Microbiota in Inflammation and Cancer
Mjesto i datum
Online, 18.09.2021. - 18.09.2021
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Helicobacter pylori
Sažetak
Background: After a first eradication attempt, approximately 10-20% of patients will fail to achieve H. pylori eradication. Aims: To evaluate the effectiveness of second-line empirical treatments. Methods: A systematic prospective registry of the clinical practice of European gastroenterologists (31 countries) on H. pylori management was established. All infected adult patients were systematically registered at AEG-REDCap e-CRF until February 2021. Modified intention-to-treat (mITT) and per- protocol (PP) analyses were performed. Results: Overall, 5, 228 patients received a second-line empirical therapy. Overall effectiveness was 84% (both by mITT and PP). Over 97% of patients were compliant. AEs were reported in 28% of the cases. Most frequent second-line prescriptions and effectiveness per antibiotic combination is shown in table 1. After failure of first-line clarithromycin-containing treatment, optimal eradication (>90%) was obtained with moxifloxacin-containing triple therapy, or quadruple therapy with levofloxacin and bismuth. In patients receiving triple regimens containing levofloxacin or moxifloxacin and levofloxacin-bismuth quadruple regimens, cure rates were optimized with 14-day regimens using high doses of proton pump inhibitors (PPIs). However, Pylera® or quadruple therapy with levofloxacin and bismuth achieved consistent eradication rates regardless of the PPI dose, duration of therapy, or previous firstline treatment regimen. Conclusion: Empirical second-line regimens including either 14-day triple therapies with levofloxacin or moxifloxacin, or 14-day levofloxacin-bismuth quadruple or 10-day bismuth quadruple therapies provided optimal effectiveness. However, many other second-line treatments evaluated reported low eradication rates.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
